title: Brivaracetam UCB.
abstract: Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the potential treatment of neurological disorders, namely epilepsy and neuropathic pain. By December 2003, UCB reported that phase II epilepsy trials had begun [517569].
authors.affiliation: Jagiellonian University Medical College, Department of Physicochemical Drug Analysis, Medyczna 9, 30-688 Krakow, Poland. mfmalaws@cyf-kr.edu.pl
authors.forename: Barbara
authors.initials: B
authors.lastname: Malawska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Kulig
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D015394:Molecular Structure; D009437:Neuralgia / Q000188:drug therapy; D011760:Pyrrolidinones / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D011760:Pyrrolidinones; C482793:brivaracetam